Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)
NCT02831088 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 210
Last updated 2017-07-13
Summary
Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute ischemic stroke patients receiving endovascular treatment to remove clot within 8 hours following stroke onset. Neu2000KWL will be administered before endovascular treatment.
Conditions
Interventions
- DRUG
-
Neu2000KWL High-does group
1st infusion of 750mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
- DRUG
-
Neu2000KWL Low-does group
1st infusion of 500mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
- DRUG
-
1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
Sponsors & Collaborators
-
GNT Pharma
lead INDUSTRY
Principal Investigators
-
Ji Man Hong, MD, PhD · Ajou University Medical Centre
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-07-31
- Primary Completion
- 2018-12-30
- Completion
- 2018-12-30
Countries
- South Korea
Study Locations
More Related Trials
-
Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
NCT00272909 ·Status: TERMINATED ·Phase: PHASE2
-
Efficacy, Safety, Tolerability and Pharmacokinetics of SUN13837 to Treat Acute Stroke
NCT02258880 ·Status: WITHDRAWN ·Phase: PHASE2
-
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
NCT00061022 ·Status: COMPLETED ·Phase: PHASE3
-
Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke
NCT04950790 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety Study of Neu2000KWL for Acute Ischemic Stroke Patients Within 6 Hours of Onset
NCT04486430 ·Status: COMPLETED ·Phase: PHASE2
-
An Exploratory Study of Ganglioside GM1 in Acute Ischemic Stroke
NCT04952064 ·Status: COMPLETED ·Phase: PHASE4
-
MLC1501 Study Assessing Efficacy in STROke Recovery
NCT05046106 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Safety and Pharmacokinetics of MCI-186 in Subjects With Acute Ischemic Stroke
NCT00821821 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Interleukin-6 Receptor Inhibitor Combined With Endovascular Treatment in Patients With Acute Anterior Circulation Large Vessel Occlusion Stroke -2
NCT07263776 ·Status: RECRUITING ·Phase: PHASE3
-
Y-6 Sublingual Tablets for Patients With Acute Ischemic Stroke
NCT07040085 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Transcranial Ultrasound in Clinical SONothrombolysis
NCT00504842 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Clinical Trial to Evaluate the Efficacy and Safety of JPI-289 in Patients With Acute Ischemic Stroke
NCT03062397 ·Status: UNKNOWN ·Phase: PHASE2
-
Human Induced Neural Stem Cell-derived Exosomes for Treating Acute Ischemic Stroke
NCT07143786 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke
NCT05836740 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS
NCT04091945 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Renexin CR in Patients With Acute Non-cardioembolic Ischemic Stroke
NCT05445895 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke
NCT01955707 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
NCT00119626 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Preliminary Efficacy Study of SA4503 in Subjects Recovering From Ischemic Stroke
NCT00639249 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of High and Low-Dose Simvastatin on Vascular Oxidative Stress and Neurological Outcome in Patients With AIS
NCT03402204 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemic Stroke
NCT07301372 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy of Sovateltide (PMZ-1620) in Patients of Acute Ischemic Stroke
NCT04047563 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of GD-iExo-003 in Acute Ischemic Stroke
NCT06138210 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Early Aggressive Strategy for Treatment of Lipid-Lowering in Acute Ischemic Stroke Delivered With Endovascular Therapy for Large Artery Occlusion
NCT07002476 ·Status: RECRUITING ·Phase: PHASE3
-
Intravenous Thrombolysis and NOAC
NCT06749834 ·Status: RECRUITING ·Phase: PHASE3